View ValuationOnyx Biotec 将来の成長Future 基準チェック /06現在、 Onyx Biotecの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長16.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 20Full year 2026 earnings released: ₹0.12 loss per share (vs ₹3.31 profit in FY 2025)Full year 2026 results: ₹0.12 loss per share (down from ₹3.31 profit in FY 2025). Revenue: ₹699.1m (up 13% from FY 2025). Net loss: ₹2.14m (down 104% from profit in FY 2025).お知らせ • May 08Onyx Biotec Limited to Report Second Half, 2026 Results on May 14, 2026Onyx Biotec Limited announced that they will report second half, 2026 results on May 14, 2026分析記事 • Jan 01We Think Onyx Biotec (NSE:ONYX) Is Taking Some Risk With Its DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Nov 13Onyx Biotec Limited to Report First Half, 2026 Results on Nov 13, 2025Onyx Biotec Limited announced that they will report first half, 2026 results on Nov 13, 2025お知らせ • Sep 02Onyx Biotec Limited, Annual General Meeting, Sep 27, 2025Onyx Biotec Limited, Annual General Meeting, Sep 27, 2025, at 12:30 Indian Standard Time.Valuation Update With 7 Day Price Move • Jun 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹54.80, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in India.New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (5.0% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹869.4m market cap, or US$10.2m).Valuation Update With 7 Day Price Move • Feb 18Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹57.40, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India.お知らせ • Jan 23Onyx Biotec Limited Announces Resignation of Harsh Jhunjhunwala as Company Secretary & Compliance OfficerOnyx Biotec Limited announced that Mr. Harsh Jhunjhunwala, Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company, has submitted his resignation effective January 22, 2025.New Risk • Jan 12New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₹1.50b market cap, or US$17.4m).Reported Earnings • Jan 11First half 2025 earnings releasedFirst half 2025 results: EPS: ₹2.24. Net income: ₹29.9m (up ₹29.9m from 1H 2024).お知らせ • Jan 11Onyx Biotec Limited to Report First Half, 2025 Results on Jan 10, 2025Onyx Biotec Limited announced that they will report first half, 2025 results on Jan 10, 2025Valuation Update With 7 Day Price Move • Jan 09Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹78.95, the stock trades at a trailing P/E ratio of 47.2x. Average trailing P/E is 34x in the Pharmaceuticals industry in India.Valuation Update With 7 Day Price Move • Dec 26Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹64.65, the stock trades at a trailing P/E ratio of 38.7x. Average trailing P/E is 35x in the Pharmaceuticals industry in India.Board Change • Nov 22High number of new directorsIndependent Director Nitesh Garg was the last director to join the board, commencing their role in 2024.お知らせ • Nov 21Onyx Biotec Limited has completed an IPO in the amount of INR 293.41 million.Onyx Biotec Limited has completed an IPO in the amount of INR 293.41 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 244,000 Price\Range: INR 61 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,366,000 Price\Range: INR 61 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 912,000 Price\Range: INR 61 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 688,000 Price\Range: INR 61 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: INR 61 Transaction Features: Regulation S このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Onyx Biotec は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NSEI:ONYX - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026695-2-65-15N/A12/31/20256794-57-26N/A9/30/202566411-50-38N/A6/30/202564230-23-12N/A3/31/202562050414N/A12/31/202461050N/AN/AN/A9/30/202460044N/AN/AN/A6/30/202456937N/AN/AN/A3/31/202453736-1715N/A3/31/202339518-16562N/A3/31/202244934-535N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ONYXの予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ONYXの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ONYXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ONYXの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ONYXの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ONYXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/15 04:21終値2026/07/15 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Onyx Biotec Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 20Full year 2026 earnings released: ₹0.12 loss per share (vs ₹3.31 profit in FY 2025)Full year 2026 results: ₹0.12 loss per share (down from ₹3.31 profit in FY 2025). Revenue: ₹699.1m (up 13% from FY 2025). Net loss: ₹2.14m (down 104% from profit in FY 2025).
お知らせ • May 08Onyx Biotec Limited to Report Second Half, 2026 Results on May 14, 2026Onyx Biotec Limited announced that they will report second half, 2026 results on May 14, 2026
分析記事 • Jan 01We Think Onyx Biotec (NSE:ONYX) Is Taking Some Risk With Its DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Nov 13Onyx Biotec Limited to Report First Half, 2026 Results on Nov 13, 2025Onyx Biotec Limited announced that they will report first half, 2026 results on Nov 13, 2025
お知らせ • Sep 02Onyx Biotec Limited, Annual General Meeting, Sep 27, 2025Onyx Biotec Limited, Annual General Meeting, Sep 27, 2025, at 12:30 Indian Standard Time.
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹54.80, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in India.
New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (5.0% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹869.4m market cap, or US$10.2m).
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹57.40, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India.
お知らせ • Jan 23Onyx Biotec Limited Announces Resignation of Harsh Jhunjhunwala as Company Secretary & Compliance OfficerOnyx Biotec Limited announced that Mr. Harsh Jhunjhunwala, Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company, has submitted his resignation effective January 22, 2025.
New Risk • Jan 12New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₹1.50b market cap, or US$17.4m).
Reported Earnings • Jan 11First half 2025 earnings releasedFirst half 2025 results: EPS: ₹2.24. Net income: ₹29.9m (up ₹29.9m from 1H 2024).
お知らせ • Jan 11Onyx Biotec Limited to Report First Half, 2025 Results on Jan 10, 2025Onyx Biotec Limited announced that they will report first half, 2025 results on Jan 10, 2025
Valuation Update With 7 Day Price Move • Jan 09Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹78.95, the stock trades at a trailing P/E ratio of 47.2x. Average trailing P/E is 34x in the Pharmaceuticals industry in India.
Valuation Update With 7 Day Price Move • Dec 26Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹64.65, the stock trades at a trailing P/E ratio of 38.7x. Average trailing P/E is 35x in the Pharmaceuticals industry in India.
Board Change • Nov 22High number of new directorsIndependent Director Nitesh Garg was the last director to join the board, commencing their role in 2024.
お知らせ • Nov 21Onyx Biotec Limited has completed an IPO in the amount of INR 293.41 million.Onyx Biotec Limited has completed an IPO in the amount of INR 293.41 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 244,000 Price\Range: INR 61 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,366,000 Price\Range: INR 61 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 912,000 Price\Range: INR 61 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 688,000 Price\Range: INR 61 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,600,000 Price\Range: INR 61 Transaction Features: Regulation S